233 related articles for article (PubMed ID: 17442410)
1. Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptase.
Kagan RM; Lee TS; Ross L; Lloyd RM; Lewinski MA; Potts SJ
Antiviral Res; 2007 Sep; 75(3):210-8. PubMed ID: 17442410
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.
Sluis-Cremer N; Sheen CW; Zelina S; Torres PS; Parikh UM; Mellors JW
Antimicrob Agents Chemother; 2007 Jan; 51(1):48-53. PubMed ID: 17088490
[TBL] [Abstract][Full Text] [Related]
3. Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.
Llibre JM; Bonjoch A; Iribarren J; Galindo MJ; Negredo E; Domingo P; Pérez-Alvarez N; Martinez-Picado J; Schapiro J; Clotet B;
HIV Med; 2008 Aug; 9(7):508-13. PubMed ID: 18484978
[TBL] [Abstract][Full Text] [Related]
4. In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.
Margot NA; Waters JM; Miller MD
Antimicrob Agents Chemother; 2006 Dec; 50(12):4087-95. PubMed ID: 16982781
[TBL] [Abstract][Full Text] [Related]
5. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
Stürmer M; Staszewski S; Doerr HW
Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153
[TBL] [Abstract][Full Text] [Related]
6. Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovir.
Barnas D; Koontz D; Bazmi H; Bixby C; Jemsek J; Mellors JW
Antivir Ther; 2010; 15(3):437-41. PubMed ID: 20516563
[TBL] [Abstract][Full Text] [Related]
7. Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.
Bradshaw D; Malik S; Booth C; Van Houtte M; Pattery T; Waters A; Ainsworth J; Geretti AM
Antimicrob Agents Chemother; 2007 Dec; 51(12):4489-91. PubMed ID: 17876005
[TBL] [Abstract][Full Text] [Related]
8. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
Gallant JE; Rodriguez AE; Weinberg WG; Young B; Berger DS; Lim ML; Liao Q; Ross L; Johnson J; Shaefer MS;
J Infect Dis; 2005 Dec; 192(11):1921-30. PubMed ID: 16267763
[TBL] [Abstract][Full Text] [Related]
9. Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF.
Delaugerre C; Roudiere L; Peytavin G; Rouzioux C; Viard JP; Chaix ML
J Clin Virol; 2005 Mar; 32(3):241-4. PubMed ID: 15722030
[TBL] [Abstract][Full Text] [Related]
10. Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen.
Descamps D; Ait-Khaled M; Craig C; Delarue S; Damond F; Collin G; Brun-Vézinet F
Antivir Ther; 2006; 11(6):701-5. PubMed ID: 17310814
[TBL] [Abstract][Full Text] [Related]
11. Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021).
Delaunay C; Brun-Vézinet F; Landman R; Collin G; Peytavin G; Trylesinski A; Flandre P; Miller M; Descamps D
J Virol; 2005 Aug; 79(15):9572-8. PubMed ID: 16014919
[TBL] [Abstract][Full Text] [Related]
12. K65R, TAMs and tenofovir.
Miller MD
AIDS Rev; 2004; 6(1):22-33. PubMed ID: 15168738
[TBL] [Abstract][Full Text] [Related]
13. Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.
Van Rompay KK; Johnson JA; Blackwood EJ; Singh RP; Lipscomb J; Matthews TB; Marthas ML; Pedersen NC; Bischofberger N; Heneine W; North TW
Retrovirology; 2007 Apr; 4():25. PubMed ID: 17417971
[TBL] [Abstract][Full Text] [Related]
14. The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients.
Winston A; Mandalia S; Pillay D; Gazzard B; Pozniak A
AIDS; 2002 Oct; 16(15):2087-9. PubMed ID: 12370512
[TBL] [Abstract][Full Text] [Related]
15. Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization.
Kagan RM; Merigan TC; Winters MA; Heseltine PN
Antivir Ther; 2004 Oct; 9(5):827-8. PubMed ID: 15535422
[No Abstract] [Full Text] [Related]
16. The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation.
Svarovskaia ES; Feng JY; Margot NA; Myrick F; Goodman D; Ly JK; White KL; Kutty N; Wang R; Borroto-Esoda K; Miller MD
J Acquir Immune Defic Syndr; 2008 Aug; 48(4):428-36. PubMed ID: 18614922
[TBL] [Abstract][Full Text] [Related]
17. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.
Røge BT; Katzenstein TL; Obel N; Nielsen H; Kirk O; Pedersen C; Mathiesen L; Lundgren J; Gerstoft J
Antivir Ther; 2003 Apr; 8(2):173-82. PubMed ID: 12741630
[TBL] [Abstract][Full Text] [Related]
18. Effect of tenofovir subtraction on HIV plasma viraemia, CD4+ T-cell count and resistance in a patient with baseline K65R and M184V mutations.
Hsu R; Lanier ER; Rouse EG; Oie KL; Pappa KA; Ross LL
Antivir Ther; 2008; 13(5):735-7. PubMed ID: 18771059
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase.
Parikh UM; Zelina S; Sluis-Cremer N; Mellors JW
AIDS; 2007 Jul; 21(11):1405-14. PubMed ID: 17589186
[TBL] [Abstract][Full Text] [Related]
20. Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen.
Kuritzkes DR
J Infect Dis; 2005 Dec; 192(11):1867-8. PubMed ID: 16267755
[No Abstract] [Full Text] [Related]
[Next] [New Search]
